|
No Identified Association Between Glecaprevir/Pibrentasvir Use and Risk of Hepatic Decompensation in HCV-Infected Patients With Compensated Cirrhosis at Baseline: An Active Comparator Cohort Study
|
|
|
Hep Dart 2019, December 8-12, 2019, Kauai, Hawaii
Reported by Jules Levin  
Lani R Wegrzyn1,2, Carrie Huisingh1,2, Ariel Porcalla2, Lino Rodrigues3, Margaret Burroughs3, Meenal Patwardhan2, Andrew Campbell3, Ryan D Kilpatrick1,21AbbVie Global Epidemiology, North Chicago, Illinois, United States; 2AbbVie Pharmacovigilance and Patient Safety, North Chicago, Illinois, United States; 3AbbVie Clinical Development, North Chicago, Illinois, United States
![1212191](../images/121219/121219-7/1212191.gif)
![1212192](../images/121219/121219-7/1212192.gif)
![1212193](../images/121219/121219-7/1212193.gif)
![1212194](../images/121219/121219-7/1212194.gif)
![1212195](../images/121219/121219-7/1212195.gif)
![1212196](../images/121219/121219-7/1212196.gif)
![1212197](../images/121219/121219-7/1212197.gif)
![1212198](../images/121219/121219-7/1212198.gif)
![1212199](../images/121219/121219-7/1212199.gif)
| |
|
|
|
|
|